Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Nanotechnology has become a powerful tool to potentially translate nanomedicine from bench to bedside. Nanotherapeutics are nanoparticles (NPs) loaded with drugs and possess the property of tissue targeting after surfaces of NPs are bio-functionalized. Designing smaller size of nanotherapeutics is presumed to increase tumor targeting based on the EPR (enhanced permeability and retention) effect. Since the immune systems possess a defence mechanism to fight diseases, there is an emerging concept that NPs selectively target immune cells to mediate the active delivery of drugs into sites of disease. In this review, we will focus on a key question of how nanotherapeutics specifically target immune cells and hijack them as a delivery vehicle to transport nanotherapeutics into disease tissues, thus possibly improving current therapies in inflammation, immune disorders and cancers. We will also discuss the challenges and opportunities for this new strategy of leukocyte-mediated delivery of nanotherapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Atherosclerosis
Libby, P., Ridker, P. M., & Maseri, A. (2002) · Circulation · doi:10.1161/hc0902.104353 · Cited by 7,724
Origin and physiological roles of inflammation
Medzhitov, R. (2008) · Nature · doi:10.1038/nature07201 · Cited by 6,618 · cited 3×
“At the site of inflammation, the vasodilation of blood vessels and their increased permeability are caused by the release of small immune-mediating molecules such as histamine, serotonin and prostaglandins [17].”
BackgroundInfluentialNeutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472 · cited 2×
“There are several novel properties of neutrophils as a carrier to deliver nanotherapeutics: 1) Neutrophils are the first cell type to arrive at inflammatory sites; 2) While the lifetime of neutrophils is short in circulation, the number of neutrophils can be increased by tens-hundreds of folds in a short period to res…”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“After the administration of nanotherapeutics in patients, they encounter several biological barriers before arriving at targets, such as blood vessels, cell membranes, and subcellular locations of drug action [3-10].”
BackgroundInnate and adaptive immune cells in the tumor microenvironment
Gajewski, T. F., Schreiber, H., & Fu, Y.-X. (2013) · Nature Immunology · doi:10.1038/ni.2703 · Cited by 4,148
Tumor-Associated Macrophages: From Mechanisms to Therapy
Noy, R., & Pollard, J. W. (2014) · Immunity · doi:10.1016/j.immuni.2014.06.010 · Cited by 4,089
Central Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067
Monocyte recruitment during infection and inflammation
Shi, C., & Pamer, E. G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3070 · Cited by 3,015 · cited 1×
“Based on the migration ability of monocytes and macrophages to the inflammation sites [84], a number of studies have demonstrated the utilization of monocytes/macrophages to transport nanoparticles [25, 85].”
BackgroundThe tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · cited 1×
“Tumor-infiltrating lymphocytes are a major component to stop the formation of tumor microenvironment and prevent the tumor growth, because T cells specifically recognize tumor-associated antigens [70].”
BackgroundCancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343 · cited 1×
“The leukocyte infiltration is regulated by various cytokines [50] and chemokines [56] produced by tumor cells.”
Background
Cited by
Advances in nanomaterial-based targeted drug delivery systems
Cheng, X., Xie, Q., & Sun, Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1177151 · Cited by 395
Neutrophil‐Based Drug Delivery Systems
Chu, D., Dong, X., Shi, X., Zhang, C., & Wang, Z. (2018) · Advanced Materials · doi:10.1002/adma.201706245 · Cited by 386
Self-citationCell membrane coated nanocarriers - an efficient biomimetic platform for targeted therapy
Dash, P., Piras, A. M., & Dash, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.012 · Cited by 260
Recent Advances in Macrophage-Mediated Drug Delivery Systems
Liang, T., Zhang, R., Liu, X., Ding, Q., Wu, S., Li, C., Lin, Y., Ye, Y., Zhong, Z., & Zhou, M. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s298159 · Cited by 126
Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy
Deng, R., Shen, N., Yang, Y., Yu, H., Xu, S., Yang, Y.-W., Liu, S., Meguellati, K., & Yan, F. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.013 · Cited by 106
Metadata
- Authors
- Dong, X., Chu, D., & Wang, Z.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2017
- Volume
- 7
- Issue
- 3
- Pages
- 751-763
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2591288833
- Cited by
- 136
- References
- 29
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. https://app.cochat.ai/papers/10.7150/thno.18069
- The paper
- Dong, X., Chu, D., & Wang, Z. (2017). Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. Theranostics. https://doi.org/10.7150/thno.18069
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.